Patents Examined by Anne Marie S. Wehbe
-
Patent number: 9944695Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: GrantFiled: April 30, 2014Date of Patent: April 17, 2018Assignee: Merus N.V.Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. De Kruif, Erwin Houtzager
-
Patent number: 9944901Abstract: Provided is a protein coded by a gene related to cell totipotency and a transcriptional activation domain of a mammalian YAP protein or a fusion protein of a segment with a transcriptional control activity, a coding nucleotide sequence, an expression vector and a composition thereof, as well as a method for inducing the pluripotent stem cells by using the fusion protein.Type: GrantFiled: June 17, 2014Date of Patent: April 17, 2018Assignees: Institute of Zoology, Chinese Academy of Sciences, Emory University School of MedicineInventors: Dahua Chen, Peng Jin, Qinmiao Sun, Weiqi Tan
-
Patent number: 9937196Abstract: In this application is described the complete genomic sequence of avian parmyxovirus type 2, strains Yucaipa, England, Kenya and Bangor. The sequences are useful for production of recombinant infective virus, a virus vector, for vaccine development and for therapeutic compositions.Type: GrantFiled: June 21, 2010Date of Patent: April 10, 2018Assignees: University of Maryland, College Park, The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Siba K. Samal, Peter L. Collins
-
Patent number: 9930871Abstract: Non-human animals, e.g., mammals, e.g., mice or rats, are provided comprising an immunoglobulin heavy chain locus that comprises a rearranged human immunoglobulin heavy chain variable region nucleotide sequence. The rearranged human immunoglobulin heavy chain variable region nucleotide sequence may be operably linked to a heavy or light chain constant region nucleic acid sequence. Also described are genetically modified non-human animals comprising an immunoglobulin light chain locus comprising one or more but less than the wild type number of human immunoglobulin light chain variable region gene segments, which may be operably linked to a light chain constant region nucleic acid sequence. Also provided are methods for obtaining nucleic acid sequences that encode immunoglobulin light chain variable domains capable of binding an antigen in the absence of a heavy chain.Type: GrantFiled: December 7, 2015Date of Patent: April 3, 2018Assignee: Regeneron Pharmaceuticals, Inc.Inventors: John McWhirter, Cagan Gurer, Karolina A. Meagher, Lynn Macdonald, Andrew J. Murphy
-
Patent number: 9931360Abstract: A method of treating liver-based inborn, metabolic deficiencies is disclosed by treatment of an individual, such as a patient suffering from liver-based inborn, metabolic deficiencies, with human progenitor or stem cells, a cell population or their progeny. The cells used in the treatment have the following characteristics. They are positive for vimentin, ?-smooth muscle actin (ASMA), and for at least one mesenchymal marker such as CD90, CD29, CD73, and CD44. They are positive for at least one hepatocyte marker such as albumin, alpha-fetoprotein, alpha-1 antitrypsin, HNF-4 and MRP2 transporter. They express at least one hepatocyte-like property or function such as G6P, CYP1B1, CYP3A4, TDO, TAT, GS, GGT, CK8, and EAAT2. They are negative for at least one marker such as cytokeratin-19, CD45, CD34, CD49f, CD133, HLA-DR, and CD117. They have mesenchymal-like morphology. They originate from human adult liver cells.Type: GrantFiled: August 25, 2017Date of Patent: April 3, 2018Assignee: UNIVERSITE CATHOLIQUE DE LOUVAINInventors: Etienne Sokal, Mustapha Najimi
-
Patent number: 9901083Abstract: Genetically modified non-human animals and methods and compositions for making and using the same are provided, wherein the genetic modification comprises a humanization of an endogenous signal-regulatory protein gene, in particular a humanization of a SIRP? gene. Genetically modified mice are described, including mice that express a human or humanized SIRP? protein from an endogenous SIRP? locus.Type: GrantFiled: June 6, 2017Date of Patent: February 27, 2018Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Andrew J. Murphy, O. Gavin Thurston, Bindu Varghese, Cagan Gurer
-
Patent number: 9901081Abstract: This invention provides a transgenic mouse with a p16INK4a promoter sequence that controls expression of a protein such that it is expressed preferentially in senescent cells. The protein either directly induces apoptosis, or converts a prodrug to a cytotoxic compound. In addition, the mouse is injected with syngeneic tumor cells, or has second transgene that causes tumors to form. Removing senescent cells from the mouse may result in the formation of fewer tumors.Type: GrantFiled: March 25, 2016Date of Patent: February 27, 2018Assignees: Buck Institute for Research on Aging, Erasmus University Medical Center RotterdamInventors: Judith Campisi, Marco Demaria, Francis Rodier, Remi-Martin Laberge, James Mitchell, Jan H. J. Hoeijmakers, Wendy Toussaint
-
Patent number: 9901080Abstract: This invention provides a transgenic mouse for studying the role of senescent cells on an age-related disorder or an age-sensitive trait. The transgene contains a p16 promoter sequence that controls expression of an enzyme so as to cause the enzyme to be expressed in senescent cells in the mouse. The enzyme converts a prodrug to a cytotoxic agent, so that treating the mouse with the prodrug results in the prodrug selectively killing the senescent cells. As a result, progression of an age-related disorder or an age-sensitive trait is delayed. Included is the 3MR mouse model, which also expresses bioluminescent and fluorescent markers under control of the p16 promoter so that senescent cells in the mice can be visualized.Type: GrantFiled: March 11, 2016Date of Patent: February 27, 2018Assignees: Buck Institute for Research on Aging, Erasmus University Medical Center RotterdamInventors: Judith Campisi, Marco Demaria, Remi-Martin Laberge, Francis Rodier, James Mitchell, Jan H. J. Hoeijmakers, Wendy Toussaint
-
Patent number: 9894889Abstract: A transgenic non-human mammal has a genome that includes an early-immediate enhancer of human cytomegalovirus (CMV enhancer), a ?-actin promoter and the entire gene region of human matrix metalloproteinase 2 (hMMP2) disposed downstream of the promoter. The hMMP2 is systemically expressed in the transgenic non-human mammal, which thus provides a suitable animal model for studying chronic obstructive pulmonary disease and related diseases and conditions.Type: GrantFiled: December 10, 2014Date of Patent: February 20, 2018Assignee: MIE UNIVERSITYInventors: Esteban C. Gabazza, Osamu Taguchi, Tetsu Kobayashi
-
Patent number: 9855328Abstract: The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the invention relates to recombinant human adenovirus vectors for delivery of avian immunogens and antigens, such as avian influenza into avians. The invention also provides methods of introducing and expressing an avian immunogen in avian subjects, including avian embryos, as well as methods of eliciting an immunogenic response in avian subjects to avian immunogens.Type: GrantFiled: September 6, 2013Date of Patent: January 2, 2018Assignees: AUBURN UNIVERSITY, ALTIMMUNE INC.Inventors: De-Chu C. Tang, Kent R. Van Kampen, Haroldo Toro
-
Patent number: 9848587Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human T cell co-receptor polypeptides (e.g., CD4, CD8?, CD8?), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same.Type: GrantFiled: February 20, 2014Date of Patent: December 26, 2017Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lynn Macdonald, Andrew J. Murphy, Naxin Tu, Cagan Gurer
-
Patent number: 9827307Abstract: Eliciting a systemic antitumor immune response can be efficacious for a patient who presents with or who is at risk of developing multiple metastatic tumors of a given cell type. To this end a pharmaceutical composition is employed that comprises a defective HSV vector, preferably containing an expressible nucleotide sequence encoding at least one immune modulator.Type: GrantFiled: February 15, 2013Date of Patent: November 28, 2017Assignee: Georgetown UniversityInventors: Samuel D. Rabkin, Masahiro Toda, Robert L. Martuza
-
Patent number: 9820476Abstract: The invention relates generally to genetically modified non-human animals expressing human polypeptides and their methods of use.Type: GrantFiled: September 6, 2013Date of Patent: November 21, 2017Assignees: Regeneron Pharmaceuticals, Inc., Yale University, Institute for Research in Biomedicine (IRB)Inventors: Richard Flavell, Markus Manz, Anthony Rongvaux, Till Strowig, Tim Willinger, Andrew J. Murphy, Sean Stevens, George Yancopoulos
-
Patent number: 9803174Abstract: This invention provides populations of neural progenitor cells, differentiated neurons, glial cells, and astrocytes. The populations are obtained by culturing stem cell populations (such as embryonic stem cells) in a cocktail of growth conditions that initiates differentiation, and establishes the neural progenitor population. The progenitors can be further differentiated in culture into a variety of different neural phenotypes, including dopaminergic neurons. The differentiated cell populations or the neural progenitors can be generated in large quantities for use in drug screening and the treatment of neurological disorders.Type: GrantFiled: July 25, 2012Date of Patent: October 31, 2017Assignee: Asterias Biotherapeutics, Inc.Inventor: Melissa K. Carpenter
-
Patent number: 9796788Abstract: A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that present a choice of two human light chain variable gene segments such that the immunoglobulin light chains expresses by the mouse comprise one of the two human light chain variable gene segments. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided.Type: GrantFiled: March 13, 2013Date of Patent: October 24, 2017Assignee: Regeneron Pharmaceuticals, Inc.Inventors: John McWhirter, Lynn MacDonald, Sean Stevens, Andrew J. Murphy
-
Patent number: 9782439Abstract: Mesenchymal stem cells are pluripotent cells capable of differentiating into myocardial and vascular endothelial cells. The present invention demonstrates that the mesenchymal stem cell sheet have therapeutic potential for a severely damaged heart due to its pluripotency and in situ self-renewal capability. Mesenchymal stem cells derived from adipose tissue were cultured to prepare a mesenchymal stem cell sheet. Four weeks after induction of myocardial infarction in rats, the mesenchymal stem cell sheet was transplanted to the heart. The mesenchymal stem cell sheet were readily engrafted to the surface of the scarred myocardium, grew gradually in situ, and formed a thick layer (approximately 600 ?m) in 4 weeks. The grown transplanted mesenchymal tissue contained newly formed blood vessels, myocardial cells, and undifferentiated mesenchymal cells.Type: GrantFiled: January 27, 2006Date of Patent: October 10, 2017Assignee: JAPAN HEALTH SCIENCES FOUNDATIONInventors: Noritoshi Nagaya, Hidezo Mori, Yoshinori Miyahara
-
Patent number: 9775863Abstract: A method of treating liver-based inborn, metabolic deficiencies is disclosed by treatment of an individual, such as a patient suffering from liver-based inborn, metabolic deficiencies, with human progenitor or stem cells, a cell population or their progeny. The cells used in the treatment have the following characteristics. They are positive for vimentin, ?-smooth muscle actin (ASMA), and for at least one mesenchymal marker such as CD90, CD29, CD73, and CD44. They are positive for at least one hepatocyte marker such as albumin, alpha-fetoprotein, alpha-1 antitrypsin, HNF-4 and MRP2 transporter. They express at least one hepatocyte-like property or function such as G6P, CYP1B1, CYP3A4, TDO, TAT, GS, GGT, CK8, and EAAT2. They are negative for at least one marker such as cytokeratin-19, CD45, CD34, CD49f, CD133, HLA-DR, and CD117. They have mesenchymal-like morphology. They originate from human adult liver cells.Type: GrantFiled: July 9, 2015Date of Patent: October 3, 2017Assignee: UNIVERSITÉ CATHOLIQUE DE LOUVAINInventors: Etienne Sokal, Mustapha Najimi
-
Patent number: 9777254Abstract: The first object of the present invention is to provide an immortalized cell line derived from a thread-sail filefish. The first object of the present invention can be solved by a cell line or a passage strain thereof derived from a living body part of a fish of the family Monacanthidae, wherein the cell line or the passage strain thereof is capable of being subcultured substantially without limitations. The second object of the present invention is to provide a pluripotent stem cell derived from a thread-sail filefish. The second object of the present invention can be solved by a cell line or a passage strain thereof derived from a living body part of a fish of the family Monacanthidae, wherein the cell line or the passage strain thereof is positive for at least a cell marker selected from a group consisting of TRA-1-60, OCT4 and SSEA-3.Type: GrantFiled: July 30, 2013Date of Patent: October 3, 2017Assignee: INDEPENDENT ADMINISTRATIVE INSTITUTION, JAPAN AGENCY FOR MARINE-EARTH SCIENCE AND TECHNOLOGYInventors: Yusuke Tsuruwaka, Tomohisa Ogawa, Yuji Hatada
-
Patent number: 9765133Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: GrantFiled: April 29, 2014Date of Patent: September 19, 2017Assignee: Merus N.V.Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. De Kruif, Erwin Houtzager
-
Patent number: 9738694Abstract: The present invention relates to a porcine alpha-S1-casein gene, a porcine alpha-S1-casein gene promoter, an expression comprising the same promoter, and a method for the production of a target protein using the same expression vector. The promoter of the present invention facilitates the mammary gland-specific expression of the target protein. Accordingly, an animal transformed with the promoter secretes the target protein in milk at high concentration, and thus can be advantageously used for the production of useful proteins.Type: GrantFiled: June 29, 2009Date of Patent: August 22, 2017Assignee: CHO-A PHARM. CO., LTD.Inventors: Myeong Goo Yeo, Sung-Jo Kang, Jong Deok Ahn